Last reviewed · How we verify
Alfarol 1.0 µg
Alfarol is an active vitamin D analog that binds to the vitamin D receptor to regulate calcium and phosphate homeostasis.
Alfarol is an active vitamin D analog that binds to the vitamin D receptor to regulate calcium and phosphate homeostasis. Used for Hypocalcemia and secondary hyperparathyroidism in chronic kidney disease, Hypoparathyroidism, Vitamin D-dependent rickets.
At a glance
| Generic name | Alfarol 1.0 µg |
|---|---|
| Sponsor | Eli Lilly and Company |
| Drug class | Vitamin D analog |
| Target | Vitamin D receptor (VDR) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Metabolic disorders |
| Phase | FDA-approved |
Mechanism of action
Alfarol (alfacalcidol) is a synthetic analog of calcitriol, the active form of vitamin D3. It binds to vitamin D receptors in target tissues, primarily in the intestine and bone, to enhance calcium absorption and regulate mineral metabolism. This mechanism makes it useful in treating conditions characterized by impaired vitamin D activation or mineral metabolism disorders.
Approved indications
- Hypocalcemia and secondary hyperparathyroidism in chronic kidney disease
- Hypoparathyroidism
- Vitamin D-dependent rickets
- Osteoporosis
Common side effects
- Hypercalcemia
- Hyperphosphatemia
- Nausea
- Headache
- Weakness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alfarol 1.0 µg CI brief — competitive landscape report
- Alfarol 1.0 µg updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI